Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities (P12-2.004)
This post hoc analysis of a phase 3 trial (NCT03030599) assessed low-sodium oxybate (LXB; Xywav®) efficacy and safety in narcolepsy participants with or without psychiatric/neurologic comorbidities.
Authors
- Craig Chepke (ORCID: https://orcid.org/0000-0002-4873-4770)
- Shawn Candler (ORCID: https://orcid.org/0000-0003-2348-9112)
- Brian Scheckner
- Nathaniel F. Watson (ORCID: https://orcid.org/0000-0003-4870-080X)
- Thomas Measey
- Douglas S. Fuller (ORCID: https://orcid.org/0000-0002-2448-5896)
- Andrew J. Cutler (ORCID: https://orcid.org/0000-0001-5800-0378)
- Sarah Akerman (ORCID: https://orcid.org/0000-0003-0866-5245)
Institutions
- University of Washington (US)
- SUNY Upstate Medical University (US)
- Jazz Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210363
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00